Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


12345678910111213...6263»
  • ||||||||||  Journal:  Emerging integrase resistance in an international perinatal virtual clinic. (Pubmed Central) -  Jan 29, 2025   
    No abstract available Although uncommon, INSTI resistance is emerging, mainly in highly treatment experienced CAWHIV from LMIC, highlighting the global need for access to boosted protease inhibitors and novel classes, including formulations for children less than 35?kg.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia. (Pubmed Central) -  Jan 16, 2025   
    The use of dolutegravir, an integrase strand transfer inhibitor (INSTI), as a first-line treatment underscores the need for detailed data on INSTI drug resistance mutations (DRMs)...The most common DRMs detected were non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs, with prevalences of 14.6% and 7% in pre-treatment and ARV-treated patients, respectively. In conclusion, CRF01_AE emerged as the predominant subtype in both pre-treatment and ARV-treated patients in Bandung, underscoring the necessity for ongoing surveillance of integrase DRMs, particularly given the presence of major INSTI DRMs in patients undergoing INSTI treatment.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion:  LoDoCA: Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV (clinicaltrials.gov) -  Jan 13, 2025   
    P=N/A,  N=258, Completed, 
    However, in light of the existing evidence of association of dolutegravir (DTG) with significant weight gain, and the recent inclusion of DTG in the first-line ART regimen nationally in India, robust surveillance and large-scale studies are recommended to study the contribution of DTG to MASLD in PLHIV, if any. Active, not recruiting --> Completed
  • ||||||||||  Journal:  Major role of dolutegravir in the emergence of the S147G integrase resistance mutation. (Pubmed Central) -  Jan 12, 2025   
    In this French study, S147G emerged principally in patients on dolutegravir regimens, in association with up to five other INSTI resistance mutations. This accumulation of mutations suggests a replicative advantage on HIV strains under dolutegravir selection pressure, suggesting that caution is required when interpreting dolutegravir resistance in the presence of such S147G resistance patterns, even in patients prescribed dolutegravir twice daily.
  • ||||||||||  efavirenz / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Retrospective data, Journal:  Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: A retrospective cohort study. (Pubmed Central) -  Jan 12, 2025   
    This accumulation of mutations suggests a replicative advantage on HIV strains under dolutegravir selection pressure, suggesting that caution is required when interpreting dolutegravir resistance in the presence of such S147G resistance patterns, even in patients prescribed dolutegravir twice daily. DTG-based ART was not significantly associated with increased BW and cholesterol levels compared with EFV-based ART in treatment-na
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion:  Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) -  Jan 9, 2025   
    P4,  N=155, Completed, 
    This underlines the need to further optimize ART in pregnancy and improve perinatal outcomes of WHIV. Active, not recruiting --> Completed
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    PK/PD data, Review, Journal:  Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review. (Pubmed Central) -  Dec 23, 2024   
    This review concludes that while PGx testing may help explain some variability in DTG pharmacokinetics when combined with therapeutic drug monitoring (TDM), current evidence is insufficient to support its routine clinical use. The role of PGx research for DTG remains relevant, especially in specific patient populations where interindividual PK variations are still unexplained.
  • ||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Transmitted antiretroviral drug resistance to Integrase Strand Transfer Inhibitors class in S (Pubmed Central) -  Dec 2, 2024   
    It shares similar resistance profile to dolutegravir, the cornerstone of Brazilian antiretroviral (ARV) treatment, with about 600 thousand people living with HIV in Brazil currently on regimens that contain this INSTI...Intermediate rates of transmitted resistance to other ARV classes are comparable to previous estimates. Viral suppression rates may depend on TCD4 counts, another negative impact of late diagnosis in care that deserves more attention.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts. (Pubmed Central) -  Nov 28, 2024   
    In West Africa, a 12-month DTG exposure was associated with substantial weight gain, especially in PLHIV previously on EFV and PI-based ARTs. Continuous weight monitoring and metabolic profiling is imperative in HIV cohorts to delineate the long-term cardiometabolic impact of DTG as patients with, or at elevated risk for cardiovascular diseases might benefit from alternative ART regimens.
  • ||||||||||  bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    Review, Journal:  Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives. (Pubmed Central) -  Nov 27, 2024   
    In this manuscript, we review weight changes among PLWH receiving HAART and the relevant underlying pathogenic mechanisms described in recent literature. We try to provide a more critical appraisal of the available data and to underline the challenges in assessing the role of HAART in weight changes in both ART initiation and setting switching.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Exposure to the antiretroviral drug dolutegravir impairs structure and neurogenesis in a forebrain organoid model of human embryonic cortical development. (Pubmed Central) -  Nov 21, 2024   
    Mechanistically, RNA-sequencing and immunohistological analysis suggests dysregulated amino acid transport and activation of the integrated stress response in the DTG-treated organoids, and functionally, a small molecule integrated stress response inhibitor (ISRIB) could partially rescue increased expression of proteins related to cell cycle regulation. Together, these results illustrate the potential for human iPSC-based strategies to reveal biological processes during neurogenesis that may be affected by therapeutic drugs and provide complementary data in relevant human cell types to augment preclinical investigations of drug safety during pregnancy.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical data, Journal:  Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women. (Pubmed Central) -  Nov 20, 2024   
    Applying the model in breastfed infants, a 1.5-, 1.7-, and 2.2-fold higher exposure in 2-day-old neonates, 10-day-old neonates, and infants who were UGT1A1 PMs, respectively, compared with EMs of the same age. However, it should be noted that the exposure in breastfed infants who were UGT1A1 PMs was still an order of magnitude lower than maternal exposure with a relative infant daily dose of <2%, suggesting safe use of dolutegravir in breastfeeding women.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Cutaneous Cytomegalovirus Ulcers in an Individual with Acquired Immunodeficiency Syndrome: A Case Report. (Pubmed Central) -  Nov 20, 2024   
    After 2 weeks, antiretroviral therapy (ART) was reinitiated with Tenofovir disoproxil fumarate, Lamivudine, and Dolutegravir. A high index of suspicion should always be maintained for CMV cutaneous ulcers in individuals with advanced immunosuppression.